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Abstract 
Background: Lipoprotein(a) (Lp(a)) is a low-density lipoprotein-like particle largely 
independent of known risk factors for, and predictive of, cardiovascular disease (CVD). We 
investigated the association between baseline Lp(a) levels and the progression of coronary artery 
calcification (CAC) in patients with hypercholesterolemia undergoing statin therapy. 
Methods: This study was a sub-analysis of a multicenter prospective study that evaluated the 
annual progression of CAC under intensive and standard pitavastatin treatment with or without 
eicosapentaenoic acid in patients with an Agatston score of 1 to 999, hypercholesterolemia 
treated with statins. Patients were classified into three groups according to CAC progression. 
Results: A total of 147 patients (mean age, 67 years; men, 54%) were analyzed. The proportion 
of patients with Lp(a) >30 mg/dL significantly increased as CAC progressed (non-progression; 
5.4%, 0<CAC progression<100; 7.7%, and CAC progression >100; 23.6%, respectively). 
Logistic regression analysis showed that Lp(a) >30 mg/dL was an independent predictor of the 
annual change in Agatston score >100 (odds ratio: 6.84; 95% confidence interval: 1.58–29.53; 
p=0.01), even after adjusting for age, sex, hypertension, diabetes mellitus, current smoking, and 
body mass index. 
Conclusion: Baseline Lp(a) >30 mg/dL was a predictor of CAC progression in this population of 
patients with hypercholesterolemia undergoing statin therapy. 
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Introduction 
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL)-like particle. Apolipoprotein B is 
covalently linked to apolipoprotein(a) by a single disulfide bond. [1] Circulating concentrations 
of Lp(a) vary widely across individuals and ethnic subgroups, mediated in large part by genetic 
variations at the LPA gene locus. [2] A meta-analysis of 126 634 participants in 36 prospective 
studies found that Lp(a) was an independent risk factor for coronary heart disease and stroke. [3] 
Recent Mendelian randomization studies have linked genetic variations at the LPA locus to both 
circulating Lp(a) concentrations and the risk for cardiovascular disease (CVD), supporting a 
causal role of Lp(a) in CVD pathogenesis. [4] [5] Generic methods to modulate circulating Lp(a) 
concentrations in daily practice remain to be determined, and accumulation of evidence for the 
monitoring of patients with high Lp(a) levels (even when undergoing treatment with lipid-
lowering drugs such as statins) is crucial. [2,6] 
Among methods for assessment of CVD risk, coronary artery calcification (CAC), which 
is determined by computed tomography (CT), is an excellent marker for clinical measurement of 
the burden of CVD risk. [7] Detrano et al. reported that the adjusted risk for a coronary event 
increased by a factor of 9.67 among participants with CAC scores >300 compared with 
participants with no coronary calcification. [8] After serial assessment, progression of CAC 
scores has been proposed as a useful predictor of cardiac outcome. [9] [10] [11] We recently 
reported a prospective multicenter study (Effect of pitavastatin and EPA on coronary artery 
calcification detected by computed tomography: PEACH study) that examined the effects of 
intensive and standard pitavastatin treatment with or without eicosapentaenoic acid (EPA) on the 
annual progression of CAC. [12] In this study, we found that the overall CAC progression rate 
over 1 year was 40% and CAC progression in each group was not affected by the allocated 
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treatments. Determining the factors involved in CAC progression are of interest. 
Previous cross-sectional studies have reported an association between Lp(a) and CAC. 
[13,14] Data from a large Asian cohort of 14 583 participants suggested a robust association 
between higher Lp(a) level and CAC in both men and women, regardless of LDL cholesterol 
level and other CVD risk factors. [14] However, that study was limited by the nature of cross-
sectional studies with regard to causality. Longitudinal studies (including short-term studies) to 
confirm the progression of CAC using baseline Lp(a) levels are required. In the current study, we 
analyzed the association between baseline Lp(a) levels and annual progression of CAC in 
patients with hypercholesterolemia who were undergoing statin therapy. 
 
Methods 
Ethical considerations 
The principal study was a prospective, open-label, multicenter trial conducted between May 
2010 and August 2011. This study was approved by the Ethics Committee of Okayama 
University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences (Certificate 
No.1652) and other hospitals involved. All participants provided written informed consent before 
enrolling. The study was conducted in accordance with the principles contained within the 
Declaration of Helsinki. The study is registered at the UMIN Clinical Trials Registry 
(UMIN000003171; Effect of pitavastatin and EPA on coronary artery calcification detected by 
computed tomography: PEACH study). 
 
Study design 
The current study was a pre-specified sub-analysis of the PEACH study. [12] Eligible patients 
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were adults (>20 years old) with an Agatston score of 1 to 999, with hypercholesterolemia (LDL 
cholesterol ≥140 mg/dL at screening or taking a statin), and no history of CVD. Exclusion 
criteria were a history of coronary revascularization, including percutaneous coronary 
intervention and coronary artery bypass surgery; Agatston score of 0 or >1000; familial 
hypercholesterolemia; use of cyclosporine; and use of lipid-lowering agents excluding statins. 
Patients were enrolled after evaluation for eligibility at each institution, including baseline multi-
detector row computed tomography (MDCT) image acquisition. Participants were randomly 
allocated into the pitavastatin 2 mg/day, pitavastatin 4 mg/day, or pitavastatin 2 mg/day 
combined with EPA 1800 mg/day groups. After taking pitavastatin 2 mg/day for 2 months to 
check for tolerance, the allocated treatment was started. Baseline blood test data were obtained 
just before starting the allocated treatment. MDCT and blood tests were performed again at the 
1-year follow-up. Fig. 1 shows a flow diagram of the study design. In the principal study, we 
enrolled 217 patients at 27 centers in Japan. Among them, 157 patients were included in the 
primary analysis. Ten patients were excluded because their stored blood samples were not 
available for the measurement of Lp(a). Finally, 147 patients were included in this post-hoc 
analysis. The primary outcome of the sub-study was the association between baseline Lp(a) level 
and annul CAC progression (Agatston score). 
 
MDCT imaging and CAC analysis 
MDCT imaging was performed as described previously. [15] All recruiting sites had previous 
cardiac CT experience and were equipped with 64-slice or higher advanced CT technology. ECG 
triggering was performed at 80% of the RR interval. MDCT images were documented in a digital 
imaging and communications in medicine format, which was sent to the core laboratory at L&L 
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Co. (Osaka, Japan) for blinded analysis. Local sites generated the total Agatston score, which 
was used as the inclusion criterion of this study. A calcium threshold ≥130 Hounsfield units was 
used. As described by Agatston, the calcium score was determined by multiplying the area of 
each calcified lesion by a weighing factor corresponding to the peak pixel intensity for each 
lesion. [16] Image analysis was performed by a trained radiologist and trained cardiologist who 
were blind to the patients’ data. Disagreements in data analysis between the two observers were 
resolved by consensus. Participants were divided into three groups according to the severity of 
CAC progression over one year: no progression, 0<CAC progression≤100, and CAC progression 
>100. CAC progression was defined as any CAC increase over one year. 
 
Risk factors and laboratory analyses 
Data on demographics, smoking status, and medication were collected for each participant. 
Current smoking was defined as a history of cigarette smoking during the past year. Diabetes was 
confirmed according to the criteria of the American Diabetes Association [17] or based on a 
history of diabetes mellitus treatment. Hypertension was defined as having a seated blood 
pressure of ≥140/90 mmHg or undergoing treatment with antihypertensive medication. Body 
mass index was calculated as body weight (kg) divided by squared height (m). 
All laboratory values were determined at an independent central study laboratory (SRL 
Inc., Tokyo, Japan). Standard enzymatic methods were used to measure total cholesterol, high-
density lipoprotein (HDL) cholesterol, LDL cholesterol, and triglycerides. High-sensitivity C-
reactive protein levels were determined using an assay (Roche–Hitachi; Hitachi, Tokyo, Japan). 
Residual serum was separated and stored at −80°C, and the serum concentration of Lp(a) was 
measured using an enzyme-linked immunosorbent assay (Shino-Test Corp., Tokyo, Japan). [18] 
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Statistical analysis 
Continuous variables are mean (standard deviation) or median (25th percentile, 75th percentile), 
as appropriate. Categorical variables are frequency and proportion (%). The Kruskal–Wallis test 
was used to compare continuous variables among the groups. The chi-square test was used to 
compare categorical variables. Logistic analysis was performed to determine the odds ratio (OR) 
with 95% confidence intervals (95%CI) for the progression of CAC associated with baseline 
Lp(a) level (>30 mg/dL and <30 mg/dL). The following variables were entered into the logistic 
model: age, sex, hypertension, diabetes mellitus, current smoking, and body mass index. A p-
value <0.05 was considered statistically significant. Statistical analyses were performed using 
SPSS 27.0 for Windows (IBM Corp., Armonk, NY). 
 
Results 
Baseline characteristics 
Table 1 shows the baseline characteristics of participants. Mean age was 67 years, and 54% were 
men. Proportions of patients with hypertension and diabetes mellitus were 81% and 27%, 
respectively. The median baseline Lp(a) level was 10.2 mg/dL and 9.5% of participants (n=14) 
had an Lp(a) >30 mg/dL. 
Association between metabolic parameters and baseline Lp(a) levels 
Bivariate correlation analysis with baseline Lp(a) and other metabolic parameters showed that 
age positively correlated, and triglycerides level negatively correlated, with baseline Lp(a) level 
(Table 2). There is no correlation between baseline Lp(a) level and CAC scores. 
Comparison of variables according to CAC progression 
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At the 1-year follow-up, 110 patients (75%) showed CAC progression. When baseline 
parameters were compared among groups with no CAC progression, 0<CAC progression≤100, 
and CAC progression >100, the proportion of patients with diabetes mellitus significantly 
increased and LDL cholesterol levels significantly decreased as the severity of CAC progression 
increased (Table 3). Lp(a) levels in patients with no progression, 0<CAC progression≤100, CAC 
progression >100 were 11.6 (6.8, 17.2), 8.6 (5.0, 20.3), and 13.1 (4.1, 40.4), respectively, and did 
not differ statistically among groups (p=0.23; Kruskal–Wallis test) (Fig. 2A). The proportion of 
patients with Lp(a) >30 mg/dL in patients with CAC progression was significantly greater than 
the other groups (p=0.03) (Fig. 2B). 
Association between baseline Lp(a) and CAC progression 
Logistic analysis showed that the odds ratio of natural log-transformed Lp(a) for annual 
progression of CAC >100 was not statistically significant (OR: 1.49, 95%CI: 0.88–2.53, p=0.13). 
When the risk for annual CAC progression >100 according to baseline Lp(a) level higher or 
lower than 30 mg/dL was calculated (Table 4), those with an Lp(a) level >30 mg/dL showed a 
significantly increased risk for CAC progression compared with those with an Lp(a) level 
<30 mg/dL in the crude model (OR: 4.72, 95% CI: 1.39–16.08; Model 1) and after adjusting for 
all confounding variables (OR: 9.84, 95% CI: 1.58–29.53; Model 3). 
 
Discussion 
This study is the first to report an association between baseline Lp(a) level and CAC progression 
over a 1-year follow-up in patients with hypercholesterolemia and undergoing statin therapy. 
Patients with CAC progression >100 over the 1-year follow-up showed a greater proportion of 
high baseline Lp(a) compared with those who had no progression or CAC progression <100 with 
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LDL cholesterol lower than 100 mg/dL with statin therapy. Logistic analysis revealed that a 
baseline Lp(a) level >30 mg/dL had a 6.84-fold increased risk for CAC progression >100 
compared with those with Lp(a) <30 mg/dL. 
The findings of the current study are considered complementary to a recent sub-analysis 
of the Justification for the use of statin in prevention: An intervention trial evaluating 
rosuvastatin (JUPITER) trial, which reported that higher Lp(a) concentrations were associated 
with an increased risk for CVD events under statin therapy. [19] That sub-analysis reported that 
rosuvastatin reduced the incidence of CVD with no interaction to baseline Lp(a) levels. In the 
current study, LDL cholesterol in patients with CAC progression >100 was lower than that in 
patients with CAC progression ≤100. Taken together, it is suggested that the Lp(a) level may be a 
significant risk factor for CVD events in people with a low LDL cholesterol level undergoing 
statin therapy. Such a suggestion also has important clinical implications with regard to 
assessment (for instance, using CAC) to determine patients with a high Lp(a) level. This is 
because generic methods to modulate circulating Lp(a) concentrations in daily practice remain to 
be determined and careful monitoring of patients with a high Lp(a) level is needed. 
In terms of a clinical cutoff point for Lp(a), the 2016 Canadian Cardiovascular Society 
Guidelines for the Management of Dyslipidemia consider Lp(a) >30 mg/dl to be a risk factor, 
and suggest measuring Lp(a) to inform decision-making, particularly in patients at intermediate 
risk and those with a family history of premature CAD, and in younger patients. [20] A large 
meta-analysis showed an inflection for risk of myocardial infarction at Lp(a) >30 mg/dl. [3] Data 
from the Multi-Ethnic Study of Atherosclerosis (MESA) reported that cutoff values of Lp(a) for 
identifying the risk of CVD events differ among races, from 30 mg/dlL to 50 mg/dL. [21] 
Recently, Dr. Tsimikas reported that Lp(a) levels are skewed leftward, and most individuals (∼
10 
70%) have values in the normal range of <30 mg/dL. [22] In the current study, the median Lp(a) 
value was 10.2 mg/dL, and the proportion of patients with Lp(a) >30 mg/dL and >40 mg/dL were 
9.5% and 3.4%, respectively. Considering these, we used Lp(a) >30 mg/dL as the cutoff value for 
the high Lp(a) level, and found that high Lp(a) was a significant risk factor for CAC progression. 
However, the appropriate cutoff value for Asian populations should be determined by further 
studies. 
The mechanisms underlying the association between elevated Lp(a) and the development 
of CAC remain unclear. Elevated Lp(a) may lead to atherosclerosis when particles become 
trapped within the arterial intima, and may also serve as a carrier of oxidized phospholipids by 
apolipoprotein B 100, which may propagate atherosclerosis via inflammatory pathways. [23] In 
addition, a study reported that Lp(a) and oxidized phospholipids mediate macrophage apoptosis 
in endoplasmic reticulum-stressed macrophages by signaling through the CD36/Toll-like 
receptor 2 pathway. [24] Therefore, it is thought that Lp(a) may contribute to CAC through the 
development of atherosclerosis via multiple pathways. 
In the current study, patients with baseline Lp(a) >30 mg/dL showed a significantly 
increased risk for CAC progression with low LDL cholesterol and undergoing statin therapy. 
CAC incidence and progression is considered an excellent surrogate marker for the prediction of 
CVD risk. [7] A cross-sectional study of an Asian population reported that Lp(a) levels were 
positively associated with CAC score [14]. However, that was a cross-sectional study and could 
not therefore show a causal relationship between Lp(a) and CAC progression. Recent data from a 
health checkup program suggest that people with a baseline Lp(a) level ≥50 mg/dL have a 1.33-
fold increased risk for CAC progression compared with those with an Lp(a) level <50 mg/dL. 
[25] The current study is the first longitudinal study to evaluate the association between baseline 
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Lp(a) and CAC progression in patients with hypercholesterolemia undergoing statin therapy. 
This study has several limitations. First, as the study was of people with 
hypercholesterolemia undergoing statin therapy, the results cannot be applied to the general 
population. Second, although Agatston score as a marker for quantifying CAC is an excellent 
surrogate marker for the prediction of CVD, we only analyzed CAC progression as the endpoint, 
not actual CVD events. Therefore, we cannot conclude that there is an association between high 
Lp(a) and CVD events. Third, the duration of follow-up was 1 year. A longer follow-up period 
might reveal a difference in the impact of Lp(a) on the progression of CAC. Finally, data on 
coronary CT angiography were not available in this study. Fourth, changes in plaque volumes 
and morphology could not be evaluated. Finally, the relationship between the change in Lp(a) 
and the change in CAC remains unclear. Prospective studies for evaluating the effect of lowering 
Lp(a) on the progression of CAC are warranted to address this issue. 
 
Conclusion 
High Lp(a) played a role in CAC progression in this population of patients with 
hypercholesterolemia undergoing statin therapy. It is suggested that measuring Lp(a) levels will 
help in the risk assessment for CVD events as well as treatment options. 
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Figure legends 
Fig. 1 Flow diagram of patient enrolment 
PIT2, pitavastatin 2 mg/day; PIT4, pitavastatin 4 mg/day; EPA, eicosapentaenoic acid 1800 
mg/day; MDCT, multi-detector row computed tomography. 
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Fig. 2 Comparison of lipoprotein (Lp(a)) levels (A) and the proportion of patients with high 
Lp(a) (B) among groups classified by coronary artery calcification (CAC) progression severity 
over 1 year 
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Table 1 Patient characteristics 
 n=147 
Age (years) 67 (10) 
Sex: men, n (%) 80 (54) 
Body mass index (kg/m2) 25.0 (4.0) 
Hypertension, n (%) 118 (81) 
Diabetes mellitus, n (%) 39 (27) 
Current smoking, n (%) 22 (15) 
Lp(a) (mg/dL) 10.2 (5.0, 21.3) 
Hemoglobin A1c (%) 5.7 (0.7) 
Triglycerides (mg/dL) 117 (89, 165) 
LDL cholesterol (mg/dL) 93.6 (24.3) 
HDL cholesterol (mg/dL) 55.5 (13.7) 
Serum creatinine (mg/dL) 0.77 (0.68, 0.90) 
hsCRP (mg/L) 0.054 (0.031, 0.106) 
Agatston score 96 (25, 244) 
 
Data are mean (standard deviation), number (%), or median (25th, 75th percentiles), as 
appropriate. Lp(a), lipoprotein a; LDL, low-density lipoprotein; HDL, high-density lipoprotein; 
hsCRP, high-sensitivity C-reactive protein. 
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Table 2 Correlation between baseline Lp(a)* and other parameters 
 r p-value 
Age 0.281 0.001 
Body mass index −0.106 0.208 
Fasting blood glucose −0.178 0.033 
Hemoglobin A1c −0.06 0.530 
Total cholesterol −0.021 0.804 
Triglycerides* −0.218 0.008 
HDL cholesterol 0.06 0.492 
LDL cholesterol  −0.009 0.915 
Serum creatinine −0.089 0.287 
hsCRP* 0.015 0.853 
Agatston score* 0.124 0.136 
 
*Lp(a), triglycerides, hsCRP, and Agatston score were log-transformed. Lp(a), lipoprotein a; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive 
protein. 
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Table 3 Comparison of variables among patients with no CAC progression, 0<CAC progression≤100, and CAC progression >100 over 
1 year 
 
No progression 
(n=37) 
0<CAC progression≤100 
(n=91) 
CAC progression>100 
(n=19) 
p-value 
Age (years) 66.3 (9.4) 67.1 (10.2) 68.7 (7.1) 0.68 
Sex: men, n (%) 20(54) 45(49) 15(79) 0.06 
Body mass index (kg/m2) 25.9 (4.7) 24.9 (3.7) 23.9 (3.4) 0.26 
Diabetes mellitus, n (%) 8(22) 21(23) 10(53) 0.02 
Hypertension, n (%) 30(81) 74(81) 14(74) 0.74 
Current smoking, n (%) 8(22) 12(13) 2(11) 0.41 
Systolic blood pressure (mmHg) 134.7 (21.5) 131.0 (16.5) 131.8 (19.8) 0.68 
Diastolic blood pressure (mmHg) 76.4 (12.9) 74.4 (10.8) 73.5 (10.8) 0.74 
Hemoglobin A1c (%) 5.7 (0.6) 5.7 (0.7) 6.0 (1.0) 0.26 
Total cholesterol (mg/dL) 182.8 (30.9) 175.9 (30.9) 166.5 (31.6) 0.23 
LDL cholesterol (mg/dL) 101.4 (24.5) 93.1 (22.7) 80.7 (26.8) 0.01 
20 
Triglycerides (mg/dL) 123 (92, 128) 108 (84, 165) 141 (89, 155) 0.63 
HDL cholesterol (mg/dL) 53.5 (12.4) 56.4 (14.6) 54.8 (11.5) 0.70 
Serum creatinine (mg/dL) 0.78 (0.69, 0.86) 0.78 (0.63, 0.90) 0.76 (0.71, 0.98) 0.68 
hsCRP (mg/dL) 0.054 (0.034, 0.123) 0.051 (0.025, 0.105) 0.070 (0.038, 0.115) 0.58 
 
Lp(a), lipoprotein a; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein. 
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Table 4 Odds ratios (95% confidence intervals) for coronary artery calcification progression >100 according to baseline Lp(a) levels 
 Model 1 Model 2 Model 3 
Lp(a) ≤30 mg/dL Reference Reference Reference 
Lp(a) >30 mg/dL 4.72 (1.39–16.08), p=0.01 6.84 (1.90–32.16), p<0.01 4.88 (1.58–29.53), p=0.01 
 
Model 1: no adjustment. Model 2: adjusted for age and sex. Model 3: Model 2 + hypertension, diabetes mellitus, current smoking, and 
body mass index.  
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